# Cannabis Research Clinical Update: March 16, 2026

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-research-clinical-update-march-16-2026/
> **Published:** 2026-03-16T07:30:57-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:58:22-04:00
> **Clinical Summary:** Explore the latest cannabis research clinical update from March 16, 2026, highlighting key studies and evidence for medical cannabis use.

---

AM Study UpdateMarch 16, 2026. 20 [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) items from PubMed, sorted by clinical priority.

Evidence Watch  |  Nature medicine (2025)

[Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.](https://pubmed.ncbi.nlm.nih.gov/41023483/)

# Study Finding Summary

This phase 3 trial evaluated a full-spectrum cannabis extract (DKJ127) for chronic low back pain, addressing a treatment gap where current pharmacologic options show limited efficacy and safety concerns.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41023483/)

Evidence Watch  |  Acta paediatrica (Oslo, Norway: 1992) (2025)

[Cannabinoids for Medical Purposes in Children: A Living Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/40437694/)

# Study Summary

This living systematic review continuously evaluates safety and efficacy data of medical cannabinoids in pediatric populations, providing clinicians with updated evidence on cannabinoid use in children.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40437694/)

Evidence Watch  |  British journal of sports medicine (2026)

[Influences on the mental health and well-being of retired professional athletes from high contact team sports: a mixed methods systematic review.](https://pubmed.ncbi.nlm.nih.gov/40930571/)

# Study Summary for Cannabis Clinicians

This systematic review examines mental health prevalence and influencing factors in retired professional high-contact team sport athletes, providing evidence on psychiatric symptom patterns relevant to understanding substance use risk in this population.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40930571/)

Evidence Watch  |  Journal of medical Internet research (2024)

[Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/38536225/)

# Study Summary for Cannabis Clinicians

The Minder mobile intervention shows promise for addressing substance use and mental health challenges in university students, a population at risk for cannabis use disorders during this developmental transition period.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/38536225/)

Evidence Watch  |  Journal of anxiety disorders (2024)

[Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.](https://pubmed.ncbi.nlm.nih.gov/38266511/)

# Study Summary for Cannabis Clinicians

**Unable to provide:** The abstract is incomplete and lacks results/findings. A complete abstract with outcomes is needed to accurately describe the study’s finding and clinical relevance.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/38266511/)

Evidence Watch  |  BMJ open (2026)

[Research on Eating and Adolescent Lifestyle (REAL) 2.0: 15-year follow-up study of eating disorders and weight-related trajectories, mental health and substance use health from early adolescence to early adulthood-a Canadian cohort profile.](https://pubmed.ncbi.nlm.nih.gov/41526025/)

# REAL 2.0 Study – Cannabis Relevance

The study tracks adolescent psychosocial risk factors and their association with substance use trajectories into adulthood, providing evidence on developmental pathways relevant to cannabis initiation and use patterns in Canadian youth.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41526025/)

Evidence Watch  |  Annals of the rheumatic diseases (2026)

[Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.](https://pubmed.ncbi.nlm.nih.gov/40846590/)

# Study Summary

This randomized controlled trial evaluated cannabidiol’s efficacy and safety versus placebo for fibromyalgia pain, providing evidence clinicians need to assess CBD’s therapeutic value in this patient population.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40846590/)

Evidence Watch  |  International journal of environmental research and public health (2026)

[Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.](https://pubmed.ncbi.nlm.nih.gov/41752306/)

# Study Finding Summary

Cannabis flower and edible products showed differential effects on anxiety reduction, with daily use patterns and longitudinal outcomes varying between product types—information relevant for clinicians personalizing cannabis recommendations for [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/).

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41752306/)

Evidence Watch  |  Journal of sleep research (2026)

[Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/40631525/)

# Study Summary for Cannabis Clinicians

This pilot trial examined how single oral doses of THC and CBD affect sleep architecture and daytime function using high-density EEG, addressing gaps in understanding cannabinoid effects on sleep quality.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40631525/)

Evidence Watch  |  Clinical pharmacology and therapeutics (2026)

[Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.](https://pubmed.ncbi.nlm.nih.gov/40836528/)

CBD demonstrated no direct effect on cortical excitability in this controlled trial, suggesting its anti-seizure efficacy may depend on drug interactions rather than direct neuronal modulation.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40836528/)

Evidence Watch  |  Journal of psychiatric research (2025)

[Pre-trauma insomnia and posttraumatic alcohol and cannabis use in the AURORA observational cohort study of trauma survivors.](https://pubmed.ncbi.nlm.nih.gov/40582081/)

# Study Finding Summary

Pre-trauma insomnia predicted increased posttraumatic cannabis use in trauma survivors, suggesting cannabis clinicians should assess baseline sleep disturbance when evaluating substance use risk in traumatized patients.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40582081/)

Evidence Watch  |  JAMA health forum (2026)

[Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.](https://pubmed.ncbi.nlm.nih.gov/41719031/)

# Study Summary

Adolescent cannabis use is associated with increased risk of psychotic, bipolar, depressive, and anxiety disorders—a finding clinicians should consider when screening and counseling young patients about cannabis exposure and mental health vulnerability.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41719031/)

Evidence Watch  |  Drug and alcohol dependence (2016)

[Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents.](https://pubmed.ncbi.nlm.nih.gov/27427415/)

# Study Finding Summary

Adolescents experiencing depression and anxiety symptoms may use cannabis as a coping mechanism, suggesting clinicians should screen for internalising disorders when assessing cannabis use risk in this population.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/27427415/)

Evidence Watch  |  Journal of clinical pharmacology (2025)

[Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/40605143/)

# Study Summary

Cannabis derivatives showed promising therapeutic effects for autism spectrum disorder symptoms, providing evidence relevant to clinical applications in managing social interaction difficulties and behavioral patterns in autistic populations.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40605143/)

Evidence Watch  |  The Journal of clinical psychiatry (2024)

[Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.](https://pubmed.ncbi.nlm.nih.gov/39724097/)

# Study Finding and Clinical Relevance

Maternal cannabis use during pregnancy was associated with increased risk of autism spectrum disorder and/or attention-deficit/hyperactivity disorder in offspring, warranting counseling on neurodevelopmental risks for pregnant cannabis users.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/39724097/)

Evidence Watch  |  Cannabis and [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) (2026)

[A Randomized, Open-Label Trial to Assess Feasibility and Tolerability of Topical Cannabis Balms for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS).](https://pubmed.ncbi.nlm.nih.gov/41467893/)

# Study Summary

This feasibility trial evaluates topical cannabis balms for treating AIMSS—musculoskeletal pain affecting approximately two-thirds of postmenopausal women taking aromatase inhibitors for breast cancer.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41467893/)

Evidence Watch  |  Psychiatry research. Neuroimaging (2026)

[A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.](https://pubmed.ncbi.nlm.nih.gov/41337954/)

# Study Finding Summary

A single CBD dose modified the relationship between hippocampal glutamate levels and prefrontal brain activation during learning tasks in individuals at clinical high risk for psychosis, suggesting a potential neurobiological mechanism for CBD’s therapeutic effects.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41337954/)

Evidence Watch  |  Medicine and science in sports and exercise (2026)

[Daily Use of a Broad-Spectrum Cannabidiol Supplement Produces Detectable Concentrations of Cannabinoids in Urine Prohibited by the World Anti-Doping Agency: An Effect Amplified by Exercise.](https://pubmed.ncbi.nlm.nih.gov/40920736/)

# Study Finding Summary

Daily broad-spectrum CBD supplementation produces detectable urine levels of WADA-prohibited cannabinoids, with exercise amplifying this effect—relevant for clinicians counseling athletes on CBD product composition and drug testing risks.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/40920736/)

Evidence Watch  |  Journal of neurodevelopmental disorders (2025)

[Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.](https://pubmed.ncbi.nlm.nih.gov/41254489/)

# Study Summary

ZYN002, a transdermal cannabidiol gel, was evaluated for long-term safety and tolerability in children and adolescents with Fragile X syndrome, providing clinical data on cannabinoid treatment in pediatric neurodevelopmental disorders.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41254489/)

Evidence Watch  |  Complementary therapies in clinical practice (2025)

[Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.](https://pubmed.ncbi.nlm.nih.gov/41005282/)

# Study Finding Summary

This feasibility study evaluated the practical implementation, patient acceptance, and safety profile of medicinal cannabis interventions for endometriosis pain management, addressing a treatment gap between patient use and clinical evidence.

[Read more →](https://pubmed.ncbi.nlm.nih.gov/41005282/)

Clinical Commentary

 Dr. Caplan’s Take
 # Clinical Reflection

These 20 items signal a field in active maturation, where [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) is moving beyond anecdotal use toward condition-specific efficacy data and safety profiling, yet with notable gaps: we have emerging evidence for chronic pain and select anxiety presentations, but persistent concerns about developmental neurotoxicity, psychiatric comorbidity risks (particularly in adolescents), and the need for better product standardization to distinguish therapeutic from adverse effects. My practice increasingly requires nuanced shared decision-making that acknowledges both the legitimate therapeutic potential documented in rigorous trials and the real teratogenic and psychotogenic risks highlighted in longitudinal cohort studies, especially for vulnerable populations like pregnant women and youth.

CannabisMental HealthSubstance Use DisordersClinical Trials[Adolescent Health](https://cedclinic.com/adolescent-cannabis-use-sexual-behavior-study/)

 

💬 Join the Conversation

 

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

 

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Study+Digest+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Study+Digest+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 
 

 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[AM Study Update: March 15, 2026](https://cedclinic.com/cannabis-clinical-trials-evidence-march-15-2026/)

Review the previous day’s cannabis research update with clinical insights and study summaries relevant to medical cannabis practice.

[Read March 15 Update](https://cedclinic.com/cannabis-clinical-trials-evidence-march-15-2026/)

[AM Study Update: March 17, 2026](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-pain-update/)

Stay informed with the next day’s cannabis research update featuring new clinical trial data and evidence summaries.

[Read March 17 Update](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-pain-update/)

[Cannabinoid Clinical Trials for Mental & Substance Disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/)

Explore comprehensive clinical trial data on cannabinoids for mental health and substance use disorders, supporting evidence-based care.

[Explore Clinical Trials](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).